TRUHEALTH Heart Advance
                     TRUHEALTH Heart Advance – Advanced Cardiac
Risk Assessment for Early Detection
Heart disease continues to be one of the most serious health challenges globally, and India faces a
particularly high burden due to rapid urbanization, lifestyle changes, and increasing stress levels. In
recent years, cardiovascular conditions have begun affecting younger individuals, often without
warning symptoms. Traditional diagnostic methods such as routine cholesterol testing are no longer
sufficient to identify early or hidden cardiac risks. TRUHEALTH Heart Advance has been designed
to address this gap through a comprehensive and advanced approach to cardiac risk assessment.
TRUHEALTH Heart Advance is a premium cardiac screening package that evaluates heart health
beyond conventional lipid profiles. Conducted by Metropolis Healthcare, this package analyses a
range of advanced biomarkers that provide insight into inflammation, plaque instability, lipid particle
behavior, genetic risk, and cardiac muscle injury. Together, these markers offer a deeper, more
accurate understanding of cardiovascular health and help detect risks at a much earlier stage.
Limitations of Routine Cholesterol Testing
A standard lipid profile measures total cholesterol, LDL cholesterol, HDL cholesterol, and
triglycerides. While these markers indicate fat levels in the blood, they do not reveal how cholesterol
interacts with arterial walls or whether blood vessels are inflamed. Many individuals experience
cardiac events despite having cholesterol levels within normal limits. This occurs because
cholesterol quantity alone does not determine cardiovascular risk.
Cardiovascular disease is driven by complex biological processes including inflammation, oxidative
stress, endothelial damage, and plaque instability. Routine lipid testing fails to capture these
processes, which is why advanced biomarker analysis is essential for accurate risk prediction.
Apolipoproteins – Understanding Lipid Particle Risk
Apolipoprotein B represents the total number of atherogenic lipid particles capable of entering
arterial walls and forming plaque. Apolipoprotein A1 reflects protective HDL particles that help
remove excess cholesterol from circulation. The ratio between Apo B and Apo A1 provides a more
precise assessment of lipid-related cardiovascular risk than LDL or HDL values alone.
An elevated Apo B/Apo A1 ratio indicates increased plaque-forming potential even when traditional
cholesterol numbers appear normal. This makes apolipoprotein testing a cornerstone of advanced
cardiac risk evaluation.
Homocysteine and Vascular Injury
Homocysteine is an amino acid produced during normal metabolic processes. Elevated levels
cause direct damage to the endothelial lining of blood vessels, promoting inflammation, clot
formation, and accelerated atherosclerosis. High homocysteine levels are associated with
increased risk of heart attack, stroke, and peripheral vascular disease.
Measuring homocysteine allows early identification of vascular injury and helps guide preventive
strategies including dietary modification and supplementation.
High-Sensitivity C-Reactive Protein (HsCRP)
Inflammation is a central driver of heart disease. HsCRP is a sensitive marker that detects
low-grade inflammation within blood vessels. Elevated HsCRP levels indicate active arterial
inflammation, which significantly increases the risk of plaque formation and rupture.
HsCRP often rises years before symptoms develop, making it a powerful early warning indicator.
Routine lipid profiles do not include this marker, leaving a major risk factor unassessed.
Lp-PLA2 and Plaque Stability
Lp-PLA2 is an enzyme linked to vascular inflammation and plaque instability. It specifically reflects
inflammation occurring inside arterial plaques. Elevated levels suggest that existing plaque is
vulnerable to rupture, which can trigger heart attacks or strokes.
This marker helps distinguish between stable and unstable plaque, offering insight into the
likelihood of acute cardiovascular events rather than long-term risk alone.
Lipoprotein(a) – Genetic Risk Factor
Lipoprotein(a) is a genetically inherited lipid particle that increases cardiovascular risk
independently of cholesterol levels. Elevated Lp(a) promotes plaque formation and interferes with
normal clot breakdown. Since lifestyle changes have limited impact on Lp(a), early detection is
crucial for aggressive risk management.
High-Sensitivity Troponin-I
Troponin-I is a highly specific marker of cardiac muscle injury. High-sensitivity testing detects even
minimal myocardial damage that may occur without symptoms. Chronic low-level elevations may
indicate ongoing cardiac stress and predict future cardiovascular events.
Identifying such injury early enables timely clinical intervention and risk reduction.
Who Benefits from TRUHEALTH Heart Advance
This advanced screening is ideal for individuals above 30 years of age, especially those with
sedentary lifestyles, high stress levels, family history of heart disease, diabetes, hypertension,
smoking habits, or exposure to air pollution. It is also valuable for individuals with normal cholesterol
but unexplained fatigue, chest discomfort, or breathlessness.
Advantages of Proactive Cardiac Screening
Early detection allows preventive strategies to be implemented before irreversible damage occurs.
Lifestyle changes, nutritional optimization, targeted therapy, and regular monitoring can significantly
reduce long-term cardiovascular risk.
Why Metropolis Healthcare
Metropolis Healthcare is a trusted diagnostic leader known for precision testing, advanced
technology, and clinical expertise. All tests are conducted in NABL and ISO-certified laboratories,
ensuring accuracy, reliability, and clinically actionable reports.
Conclusion
Heart disease often develops silently, progressing for years before manifesting as a major event.
Relying solely on routine cholesterol tests can result in missed opportunities for prevention.
TRUHEALTH Heart Advance offers a comprehensive, science-driven approach to cardiac risk
assessment, enabling early detection of hidden threats.
By evaluating inflammation, plaque behavior, lipid particle dynamics, genetic risk, and myocardial
injury, this premium package supports informed, proactive heart health management. With
Metropolis Healthcare’s expertise, TRUHEALTH Heart Advance represents a critical step toward
long-term cardiovascular wellness.